03:14 , Dec 8, 2018 |  BioCentury  |  Regulation

Path to opioid-free pain relief

To jump-start development of analgesics that can help stem the opioid crisis, companies want FDA’s upcoming guidelines to reduce uncertainty around outcomes that constitute clinically meaningful opioid sparing. But while an advisory panel put some...
15:27 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

FDA approves AbbVie's Orilissa for endometriosis pain

FDA approved Orilissa elagolix from AbbVie Inc. (NYSE:ABBV) for the management of moderate to severe pain associated with endometriosis. AbbVie expects to launch the drug early next month at a wholesale acquisition cost (WAC) of...
20:44 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

ObsEva's linzagolix meets in Phase IIb for endometriosis-associated pain

ObsEva S.A. (NASDAQ:OBSV) said three of four doses of linzagolix (OBE2109, KLH-2109) met the primary endpoint in the Phase IIb EDELWEISS trial to treat moderate to severe endometriosis-associated pain. The company plans to present additional...
19:03 , Jun 22, 2018 |  BC Week In Review  |  Financial News

ObsEva raises $73M follow-on

Reproductive health company ObsEva S.A. (NASDAQ:OBSV) raised $73.1 million through the sale of 4.8 million shares at $15.39 in a follow-on underwritten by J.P. Morgan, Credit Suisse Securities (USA), Jefferies, Wedbush Securities and H.C. Wainwright....
20:13 , Jun 20, 2018 |  BC Extra  |  Financial News

ObsEva raises $73M on heels of linzagolix data

ObsEva S.A. (NASDAQ:OBSV) raised $73.1 million through the sale of 4.8 million shares at $15.39 in a follow-on underwritten by J.P. Morgan, Credit Suisse Securities (USA), Jefferies, Wedbush Securities and H.C. Wainwright. The price is...
16:20 , May 23, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mice treated prenatally with AMH could be used to screen therapies to treat polycystic ovary syndrome, a partially heritable disease. In blood samples from 66 pregnant patients with PCOS, AMH levels were...
16:32 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

AbbVie's elagolix meets in second Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-II (M12-817) trial, the second of two replicate Phase III trials of the non-peptide small molecule...
18:08 , Mar 13, 2018 |  BC Extra  |  Clinical News

AbbVie's elagolix meets in second Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-II (M12-817) trial, the second of two replicate Phase III trials of the candidate to treat...
20:34 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

AbbVie's elagolix meets in Phase III for uterine fibroids

AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met the primary and all ranked secondary endpoints in the Phase III ELARIS UF-I (M12-815) trial to treat uterine fibroids. The trial is the first of two replicate Phase...
21:12 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Other; hematology

INDICATION: Poisoning; hematology Mouse studies suggest GnRH/LHRH receptor antagonists could help treat radiation poisoning and chemotherapy-induced myelosuppression. In mice exposed to lethal whole-body radiation, the GnRH/LHRH receptor antagonist Firmagon degarelix increased counts of red blood...